trending Market Intelligence /marketintelligence/en/news-insights/trending/-XwYxhw8r0J3eymcjtslVg2 content esgSubNav
In This List

Kala Pharmaceuticals appoints director ahead of commercialization efforts

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Kala Pharmaceuticals appoints director ahead of commercialization efforts

Kala Pharmaceuticals Inc. appointed Gregory Perry to its board of directors.

Perry is the former chief financial and administrative officer of Novelion Therapeutics Inc.

"Greg brings a wealth of business, strategic and financial expertise gained during his accomplished career in the biotech industry. We look forward to benefitting from his guidance as the company matures and we continue to advance toward commercialization," Kala Chairman and CEO Mark Iwicki said in a statement.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle technology, with an initial focus on the treatment of eye diseases.